Abstract:e21123 Background: Brain or liver metastases are the main causes of lung cancer-related death. Predicting liver or brain metastases before having evidence from imaging of the tumors is challenging, but important for early patient intervention. Accumulating evidence has suggested that circulating exosomes in the blood could mediate cancer metastasis by transferring specific proteins to the target cells. Methods: Using liquid chromatography-MS/MS, we analyzed the proteomic profiles of plasma exosomes derived from 42 metastatic lung cancer patients (including 26 solitary brain metastasis (BM) and 16 solitary liver metastasis (LM)), 25 local advanced (LA) lung cancer patients without metastasis, and 5 healthy controls (HC), and explored organ-specific proteomic biomarkers. Results: 120 and 143 differentially expressed exosomal proteins were found to be the dysregulated candidates in BM and LM of lung cancer (BM-DEEPs, LM-DEEPs), as compared to the LA lung cancer samples, respectively. The bioinformatics analyses indicated the homogeneity and heterogeneity in BM-DEEPs and LM-DEEPs. In terms of homogeneity, they were mainly involved in the protein activation cascade, collagen-containing extracellular matrix, and ECM-receptor interaction. In terms of heterogeneity, the BM-DEEPs were significantly enriched in S100 protein and calcium-dependent protein, while the LM-DEEPs were mainly enriched in integrin, lipoprotein, heat shock protein and proteoglycans. Moreover, our study also revealed the heterogeneity in plasma-derived exosome proteomics in patients with non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), which partly explained the different metastatic characteristics of NSCLC and SCLC. Additionally, we found that MUC5B and SELL could be used as a reliable diagnostic marker of BM, while APOH, CD81 and CCT5 could help to diagnose LM in lung cancer patients. Conclusions: For the first time, we revealed the comprehensive and comparative proteomic profiles of plasma-derived exosomes from lung cancer patients with solitary brain and liver metastasis. We further proposed some potential biomarkers and pathological mechanisms, which could serve as excellent resource for further studies investigating lung cancer metastasis.

Analysis of Differentially Expressed Proteome in Urinary Exosome from Non-small Cell Lung Cancer Patients

Differential Proteome Profiling of Pleural Effusions from Lung Cancer and Benign Inflammatory Disease Patients

Proteomic Discovery and Array-Based Validation of Biomarkers from Urinary Exosome by Supramolecular Probe

Proteomic Analysis of Plasma Exosomes in Patients with Non-Small Cell Lung Cancer

Isolation and proteomic profiling of urinary exosomes from patients with colorectal cancer

Proteomic Characterization of Urinary Exosomes with Pancreatic Cancer by Phosphatidylserine Imprinted Polymer Enrichment and Mass Spectrometry Analysis

Size-dependent Sub-Proteome Analysis of Urinary Exosomes.

Identification of Exosome Protein Panels As Predictive Biomarkers for Non-Small Cell Lung Cancer

Urinary Exosomes: Potential Diagnostic Markers and Application in Bladder Cancer

Plasma exosomes contain protein biomarkers valuable for the diagnosis of lung cancer

The Comparison of Serum Exosome Protein Profile in Diagnosis of NSCLC Patients

Systematic Comparison of Exosomal Proteomes from Human Saliva and Serum for the Detection of Lung Cancer

Comparative Proteomic Analysis of Exosomes and Microvesicles in Human Saliva for Lung Cancer.

Analysis of differential expressed protein from SCLC patient serum

Glycoproteomic Analysis of Human Urinary Exosomes

Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation

Comparative proteomic profiling of plasma exosomes in patients with lung cancer with brain metastasis and liver metastasis.

Analysis of differential expression proteins of small cell lung cancer and matched normal lung tissues by 2-DE and MALDI-TOF-MS

Investigation of Urinary Exosome Metabolic Patterns in Membranous Nephropathy by Titania‐Assisted Intact Exosome Mass Spectrometry

Serum Exosomal Proteomics Analysis of Lung Adenocarcinoma to Discover New Tumor Markers

Comparative Proteomic Analysis of Non-small-cell Lung Cancer and Normal Controls Using Serum Label-Free Quantitative Shotgun Technology